Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 55Central Nervous System Neoplasms 53Brain Neoplasms 48Astrocytoma 30Glioblastoma 27Medulloblastoma 25Glioma 23Oligodendroglioma 21Gliosarcoma 14Optic Nerve Glioma 13Testicular Neoplasms 11Choroid Plexus Neoplasms 11Sarcoma 10Ovarian Neoplasms 10Neoplasms 10Rhabdoid Tumor 9Carcinoma, Non-Small-Cell Lung 9Testicular Germ Cell Tumor 7Teratoma 7Recurrence 7Neuroectodermal Tumors, Primitive, Peripheral 7Familial ependymoma 7Ependymoma 7Lung Neoplasms 6Spinal Cord Neoplasms 5Retinoblastoma 5Osteosarcoma 5Neuroectodermal Tumors, Primitive 5Lymphoma 5Liver Neoplasms 5

Interventions

trametinib 2dabrafenib 2mirdametinib 1gallium Ga 68 dotatate 1Vincristine 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ga(III)-DOTATOC 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroma × Carboplatin × CNS × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡